Using toxin-catalyzed ADP-ribosylation and specific immunoblots we examined whether the mass of G-protein subunits, G alpha s, G alpha i (includes G alpha i2, G alpha i3, and G alpha 0) and G alpha beta, in glomerular membranes was altered by dietary protein intake. ADP-ribosylation catalyzed by cholera toxin (CT) or pertussis toxin (PT) detected significant amounts of G alpha s or G alpha i in glomerular membranes from rats fed a low (6% casein) or a high (40% casein) protein diet. There was no significant difference in G alpha s content between glomerular membranes from low or high protein-fed rats. However, the amounts of G alpha i were significantly lower in glomerular membranes from rats fed a high protein diet when compared to glomerular membranes from rats fed a low protein diet. Two isoforms of immunoreactive G alpha s, 45 and 52 kDa proteins, were detected in glomerular membranes. The predominant isoform of G alpha s was a 52 kDa protein. As with ADP-ribosylation, immunoblots showed no significant difference in G alpha s content between glomerular membranes obtained from the two diet groups of rats. Also, immunoreactive G alpha i2, G alpha i3 and G beta were present in glomerular membranes. The mass of G alpha i2 and G alpha i3 was significantly lower in glomerular membranes of rats fed a high protein diet than in those of rats fed a low-protein diet. The decreased mass of total G alpha i, that is G alpha i2 and G alpha i3, was comparable to that seen with PT-catalyzed ADP-ribosylation.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/ki.1993.149 | DOI Listing |
Future Sci OA
December 2025
Gastroenterology Department, La Rabta Hospital, Tunis, Tunisia.
Background: Colonic stenosis in Crohn's disease (CD) is uncommon, and data on surgery-free survival are limited. This study aimed to determine surgery-free survival rates and identify associated factors.
Patients And Methods: A retrospective study was conducted from 2003 to 2022, including patients with CD complicated by colonic stenosis.
Int J Audiol
January 2025
Hashir International Specialist Clinics & Research Institute for Misophonia, Tinnitus and Hyperacusis, London and Guildford, UK.
Objective: The aim was to establish the validity and reliability of the English version of MisoQuest, a 14-item misophonia questionnaire initially validated in the Polish language.
Design: Reliability was examined through internal consistency, measurement error, and test-retest reliability. Validity was evaluated with confirmatory factor analysis, convergent, and discriminant validity.
Ann Med
December 2025
Department of Neurology, Peking University First Hospital, China.
Objective: Whereas a few studies have evaluated vestibular involvement in Fabry disease (FD), the relationship between vestibular/oculomotor abnormalities and disease-specific biomarkers remain unclear. Therefore, we seek to evaluate these quantitatively and analyze their relationship with disease phenotype and biomarkers in FD.
Methods: This cohort study enrolled 37 Chinese FD patients registered in our center.
Comput Biol Med
January 2025
Faculty of Chemistry, University of Science (Vietnam National University, Hanoi), 19 Le Thanh Tong, Hoan Kiem, Ha Noi, Viet Nam; VNU University of Education, Vietnam National University, Hanoi, 144 Xuan Thuy, Cau Giay, Ha Noi, Viet Nam.
α-d-Glucose-conjugated thioureas 8a-w of substituted 4,6-diaryl-2-aminopyrimindines were designed, synthesized, and screened for their antidiabetic inhibitory activity. The thioureas with the strongest potential inhibitory activity included 8f (IC = 11.32 ± 0.
View Article and Find Full Text PDFQual Life Res
January 2025
Value-based Health & Care Academy, School of Management, Swansea University, Swansea, SA1 8EN, UK.
Purpose: Outcome-based pricing models which consider domains of value not previously considered in healthcare, such as societal outcomes, are of increasing interest for healthcare systems. Societal outcomes can include family-reported outcome measures (FROMs), which measure the impact of disease upon the patient's family members. The FROM-16 is a generic and easy-to-use family quality of life tool, but it has never been used in the context of patients undergoing advanced therapy medicinal product (ATMP) treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!